Published in Pediatrics on September 01, 2003
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers | NCT00797420
Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev (2004) 2.45
Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics (2010) 1.86
Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother (2008) 1.68
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
Risk factors for candidemia in critically ill infants: a matched case-control study. J Pediatr (2005) 1.49
Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed (2005) 1.23
Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J (1998) 1.19
Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis (2004) 1.15
Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther (2009) 1.14
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
Characteristics of patients who die of necrotizing enterocolitis. J Perinatol (2011) 1.07
Choice and duration of antimicrobial therapy for neonatal sepsis and meningitis. Int J Pediatr (2011) 0.99
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther (2011) 0.98
Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur J Pediatr (2006) 0.95
Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting. Expert Rev Anti Infect Ther (2012) 0.95
The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol (2014) 0.90
Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed (2007) 0.89
Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf (2011) 0.87
Intrauterine Candida albicans infection elicits severe inflammation in fetal sheep. Pediatr Res (2014) 0.83
Outcomes of neonatal candidiasis: the impact of delayed initiation of antifungal therapy. Int J Pediatr (2011) 0.80
Risk factors for invasive candidiasis in infants >1500 g birth weight. Pediatr Infect Dis J (2013) 0.79
The role of procalcitonin in neonatal intensive care unit patients with candidemia. Folia Microbiol (Praha) (2012) 0.79
Neonatal candidiasis: diagnosis, prevention, and treatment. J Infect (2014) 0.78
Successful management of fungal pericarditis and endocarditis in a neonate: A case report. J Saudi Heart Assoc (2012) 0.78
Neonatal fungal infections: when to treat? Early Hum Dev (2012) 0.77
Advances in the treatment of invasive neonatal candidiasis. Expert Opin Pharmacother (2015) 0.76
Incidence of Breakthrough Urinary Tract Infection in Hospitalized Infants Receiving Antibiotic Prophylaxis. Clin Pediatr (Phila) (2016) 0.75
Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2005) 0.75
Usefulness of direct fluorescent in buffy coat in the diagnosis of Candida sepsis in neonates. J Perinatol (2016) 0.75
Platelet parameters and (1, 3)-β-D-glucan as a diagnostic and prognostic marker of invasive fungal disease in preterm infants. PLoS One (2015) 0.75
Fungal endocarditis in a premature infant complicated by a right atrial mycetoma and inferior vena cava thrombosis. Images Paediatr Cardiol (2009) 0.75
Impact of neonatal early-onset sepsis calculator on antibiotic use within two tertiary healthcare centers. J Perinatol (2016) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 4.39
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
New intrauterine growth curves based on United States data. Pediatrics (2010) 3.72
Procedural volume as a marker of quality for CABG surgery. JAMA (2004) 3.70
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg (2009) 3.45
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis (2004) 2.98
Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA (2002) 2.98
A decade of change--risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg (2002) 2.91
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg (2003) 2.86
Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med (2005) 2.79
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Quality measurement in adult cardiac surgery: part 1--Conceptual framework and measure selection. Ann Thorac Surg (2007) 2.60
Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol (2012) 2.59
Quality measurement in adult cardiac surgery: part 2--Statistical considerations in composite measure scoring and provider rating. Ann Thorac Surg (2007) 2.59
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions. Semin Perinatol (2006) 2.28
Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J (2007) 2.25
Necrotizing enterocolitis among neonates in the United States. J Perinatol (2003) 2.24
Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr (2011) 2.22
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3--valve plus coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 2.18
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J (2004) 2.08
Human rhinoviruses. Clin Microbiol Rev (2013) 2.05
Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis (2006) 2.02
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 1.94
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics (2003) 1.92
Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J (2009) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics (2010) 1.86
Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a prospective cohort in the United States. Fertil Steril (2011) 1.85
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction. Arch Intern Med (2010) 1.73
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72
Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg (2004) 1.70
Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.70
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Emerging and less common fungal pathogens. Infect Dis Clin North Am (2002) 1.68
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
Hypothermia and perinatal asphyxia: executive summary of the National Institute of Child Health and Human Development workshop. J Pediatr (2006) 1.67
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J Perinatol (2004) 1.64
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis (2004) 1.64
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol (2005) 1.61
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother (2005) 1.59
A novel application of 1H magnetic resonance spectroscopy: non-invasive identification of spermatogenesis in men with non-obstructive azoospermia. Hum Reprod (2010) 1.56
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J (2008) 1.55
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 1.55
Is early too early? Effect of shorter stays after bypass surgery. Ann Thorac Surg (2007) 1.54
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
Racial differences in vasectomy utilization in the United States: data from the national survey of family growth. Urology (2009) 1.53
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53
The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful use" in continuous quality improvement. Clin Perinatol (2010) 1.52
Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics (2008) 1.49
Echinocandins--an advance in the primary treatment of invasive candidiasis. N Engl J Med (2002) 1.49
Multifaceted intervention to promote beta-blocker use in heart failure. Am Heart J (2006) 1.48
Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med (2015) 1.48
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma (2012) 1.47
Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis (2002) 1.47
Fecundity and sex ratio of offspring in an infertile cohort. Fertil Steril (2011) 1.47
Wet heat exposure: a potentially reversible cause of low semen quality in infertile men. Int Braz J Urol (2007) 1.47
Men who seek infertility care may not represent the general U.S. population: data from the National Survey of Family Growth. Urology (2011) 1.47
Economic effects of beta-blocker therapy in patients with heart failure. Am J Med (2004) 1.46